Jack Cush

A Korean insurance claims data study showed children and adolescents diagnosed with uveitis have a 7 fold increased risk of developing an immune-mediated inflammatory disorder (IMIDs).

Rheumatology has published a cohort study showing that earlyGI symptoms and overall symptom burden predict both GI progression and mortality in Systemic Sclerosis (SSc).

May 26, 2026 12:17 am Know-it-now The Lupus Nephritis (LN) trial pipeline is accelerating — and involves Southeast Asia.

May 26, 2026 9:00 am A small, pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease.

May 27, 2026 9:00 am The Wall St. Journal has published a perspective on nurse practitioners (NP) and their very promising careers.

Researchers at Semmelweis University analyzed how depression, smoking, obesity, sleep disorders, and other health problems are linked to difficult-to-treat rheumatoid arthritis (D2T-RA) and how this can inform treat-to-target (T2T) and individualized therapy.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnsons supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA).

Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States. The Australian Rheumatology Association's 2025 Workforce Report warns the nation faces a significant rheumatology manpower (adult and pediatric) shortage and may not close the gap unless there is urgent government intervention.

Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's supplemental Biologics License (sBLA) to include evidence in the guselkumab (T